Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: A randomized, double-blind, placebo-controlled trial

Journal of Neural Transmission

Volumn 117, Issue 11, 2010, Pages 1279-1286

  Wolz, Martin ^a   Löhle, Matthias ^a   Strecker, Karl ^b   Schwanebeck, Uta ^a   Schneider, Christine ^a   Reichmann, Heinz ^a   Grählert, Xina ^a   Schwarz, Johannes ^b   Storch, Alexander ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antidyskinetic effects; Double blind randomized clinical trial; Levetiracetam; Levodopa induced dyskinesia; Parkinson's disease

Indexed keywords

ETIRACETAM; LEVODOPA; PLACEBO;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADD ON THERAPY; ADULT; AGED; ARTICLE; BLADDER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EVENING DOSAGE; FEMALE; HUMAN; INFECTION; INVOLUNTARY MOVEMENT; MALE; NAUSEA; NEUROLOGIC EXAMINATION; OUTCOME VARIABLE; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; UNSPECIFIED SIDE EFFECT;

AGED; ANTIPARKINSON AGENTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 78651241450     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0472-x     Document Type: Article

References (49)

1. A Antonini IU Isaias M Canesi M Zibetti F Mancini L Manfredi M Dal Fante L Lopiano G Pezzoli 2007 Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome Mov Disord 22 8 1145 1149 10.1002/mds.21500 10.1002/mds.21500 17661426 (Pubitemid 47067225)
2. Y Awaad AM Michon S Minarik 2005 Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome Mov Disord 20 6 714 718 10.1002/mds.20385 10.1002/mds.20385 15704204 (Pubitemid 41056938)
3. E Bezard MP Hill AR Crossman JM Brotchie A Michel R Grimee H Klitgaard 2004 Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque Eur J Pharmacol 485 1-3 159 164 S0014299903027365 1:CAS:528:DC%2BD2cXnvVyitQ%3D%3D 10.1016/j.ejphar.2003.11.065 14757136 (Pubitemid 38134410)
4. KE Bloch OD Schoch JN Zhang EW Russi 1999 German version of the Epworth sleepiness scale Respiration 66 5 440 447 1:STN:280:DyaK1Mvksl2qtQ%3D%3D 10.1159/000029408 10516541 (Pubitemid 29431578)
5. T Boraud E Bezard B Bioulac CE Gross 2001 Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey Brain 124 Pt 3 546 557 1:STN:280:DC%2BD3M7ps1ChtA%3D%3D 10.1093/brain/124.3.546 11222455
6. TN Chase JD Oh 2000 Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism Trends Neurosci 23 10 Suppl S86 S91 1:CAS:528:DC%2BD3cXotVGrtLY%3D 10.1016/S1471-1931(00)00018-5 11052225
7. A Colzi K Turner AJ Lees 1998 Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease J Neurol Neurosurg Psychiatry 64 5 573 576 1:STN:280:DyaK1c3lvVKitw%3D%3D 10.1136/jnnp.64.5.573 9598668
8. S Cristina R Zangaglia F Mancini E Martignoni G Nappi C Pacchetti 2003 High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias Clin Neuropharmacol 26 3 146 150 1:CAS:528:DC%2BD3sXktlyrsL4%3D 10.1097/00002826-200305000-00008 12782917 (Pubitemid 36676293)
9. GL Defer H Widner RM Marie P Remy M Levivier 1999 Core assessment program for surgical interventional therapies in Parkinson's disease (capsit-pd) Mov Disord 14 4 572 584 1:STN:280:DyaK1MzmtFyntA%3D%3D 10.1002/1531-8257(199907)14: 4<572::AID-MDS1005>3.0.CO;2-C 10435493 (Pubitemid 30011449)
10. F Durif B Debilly M Galitzky D Morand F Viallet M Borg S Thobois E Broussolle O Rascol 2004 Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study Neurology 62 3 381 388 1:CAS:528:DC%2BD2cXlvFWmsw%3D%3D 14872017
11. AH Evans R Katzenschlager D Paviour JD O'Sullivan S Appel AD Lawrence AJ Lees 2004 Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome Mov Disord 19 4 397 405 10.1002/mds.20045 10.1002/mds.20045 15077237 (Pubitemid 38559642)
12. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22(10):1379-1389. doi: 10.1002/mds.21475 (quiz 1523)
13. Fahn S, Elton RL, Committee UD (1987) The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB (eds) Recent developments in Parkinson's disease, vol 2. Macmillan Healthcare Information, Florham Park, pp 153-163, 293-304
14. CG Goetz P Damier C Hicking E Laska T Muller CW Olanow O Rascol H Russ 2007 Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial Mov Disord 22 2 179 186 10.1002/mds.21226 10.1002/mds.21226 17094088 (Pubitemid 46374758)
15. B Gomez-Mancilla PJ Bedard 1993 Effect of nondopaminergic drugs on l-dopa-induced dyskinesias in MPTP-treated monkeys Clin Neuropharmacol 16 5 418 427 1:STN:280:DyaK2c%2Fjs1yltg%3D%3D 10.1097/00002826-199310000-00004 8106150
16. M Hamann SE Sander A Richter 2008 Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster Eur J Pharmacol 601 1-3 99 102 S0014-2999(08)01098-4 1:CAS:528:DC%2BD1cXhsVKrsbvE 10.1016/j.ejphar.2008.10.048 19014930
17. G Heimer I Bar-Gad JA Goldberg H Bergman 2002 Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism J Neurosci 22 18 7850 7855 22/18/7850 1:CAS:528:DC%2BD38Xnt12lt70%3D 12223537
18. AJ Hughes SE Daniel L Kilford AJ Lees 1992 Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 55 3 181 184 1:STN:280:DyaK383is1Omsg%3D%3D 10.1136/jnnp.55.3.181 1564476
19. R Janz Y Goda M Geppert M Missler TC Sudhof 1999 SV2A and SV2B function as redundant Ca2+ regulators in neurotransmitter release Neuron 24 4 1003 1016 S0896-6273(00)81046-6 1:CAS:528:DC%2BD3cXislaluw%3D%3D 10.1016/S0896-6273(00) 81046-6 10624962
20. R Katzenschlager AJ Manson A Evans H Watt AJ Lees 2004 Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study J Neurol Neurosurg Psychiatry 75 2 295 297 1:STN:280: DC%2BD2c%2Fnt1OrsA%3D%3D 14742609
21. R Katzenschlager A Hughes A Evans AJ Manson M Hoffman L Swinn H Watt K Bhatia N Quinn AJ Lees 2005 Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges Mov Disord 20 2 151 157 10.1002/mds.20276 10.1002/mds.20276 15390035 (Pubitemid 40361117)
22. H Klitgaard 2001 Levetiracetam: the preclinical profile of a new class of antiepileptic drugs? Epilepsia 42 Suppl 4 13 18 11564119
23. N Kumar JA Van Gerpen JH Bower JE Ahlskog 2005 Levodopa-dyskinesia incidence by age of Parkinson's disease onset Mov Disord 20 3 342 344 10.1002/mds.20360 10.1002/mds.20360 15580606 (Pubitemid 40613295)
24. A Kupsch T Trottenberg D Bremen 2004 Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study Curr Med Res Opin 20 1 115 120 10.1185/030079903125002775 1:CAS:528:DC%2BD2cXht1entrk%3D 10.1185/030079903125002775 14741081 (Pubitemid 38063463)
25. BA Lynch N Lambeng K Nocka P Kensel-Hammes SM Bajjalieh A Matagne B Fuks 2004 The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proc Natl Acad Sci USA 101 26 9861 9866 1:CAS:528: DC%2BD2cXlvVahtb8%3D 10.1073/pnas.0308208101 15210974 (Pubitemid 38869327)
26. KE Lyons R Pahwa 2006 Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia Clin Neuropharmacol 29 3 148 153 10.1097/01.WNF.0000220814.48360.F4 1:CAS:528:DC%2BD28XlsFeisro%3D 10.1097/01.WNF.0000220814.48360.F4 16772814 (Pubitemid 44503893)
27. AJ Manson A Schrag AJ Lees 2000 Low-dose olanzapine for levodopa induced dyskinesias Neurology 55 6 795 799 1:CAS:528:DC%2BD3cXntlygsLc%3D 10993998
28. DG Margineanu H Klitgaard 2000 Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs Pharmacol Res 42 4 281 285 10.1006/phrs.2000.0689 1:STN:280:DC%2BD3M%2FovF2rsg%3D%3D 10.1006/phrs.2000.0689 10987984
29. PR May MA Lee RC Bacon 1983 Quantitative assessment of neuroleptic-induced extrapyramidal symptoms: clinical and nonclinical approaches Clin Neuropharmacol 6 Suppl 1 S35 S51 1:STN:280:DyaL2c%2FlsFWhsw%3D%3D 10.1097/00002826-198300061-00006 6139165
30. T Nagatsua M Sawadab 2009 l-Dopa therapy for Parkinson's disease: past, present, and future Parkinsonism Relat Disord 15 Suppl 1 S3 S8 S1353-8020(09)70004-5 10.1016/S1353-8020(09)70004-5 19131039
31. I Niespodziany H Klitgaard DG Margineanu 2003 Desynchronizing effect of levetiracetam on epileptiform responses in rat hippocampal slices Neuroreport 14 9 1273 1276 10.1097/01.wnr.0000081866.45938.bf 1:CAS:528:DC%2BD3sXlt1Whtbo%3D 10.1097/00001756-200307010-00017 12824774
32. P Odin C Oehlwein A Storch U Polzer G Werner R Renner M Shing A Ludolph P Schuler 2006 Efficacy and safety of high-dose cabergoline in Parkinson's disease Acta Neurol Scand 113 1 18 24 1:CAS:528:DC%2BD28XislKhtrs%3D 10.1111/j.1600-0404.2005.00514.x 16367894
33. PN Patsalos 2000 Pharmacokinetic profile of levetiracetam: toward ideal characteristics Pharmacol Ther 85 2 77 85 S0163-7258(99)00052-2 1:CAS:528:DC%2BD3cXosFSnsA%3D%3D 10.1016/S0163-7258(99)00052-2 10722121 (Pubitemid 30069478)
34. PN Patsalos 2004 Clinical pharmacokinetics of levetiracetam Clin Pharmacokinet 43 11 707 724 1:CAS:528:DC%2BD2cXnvVGms7c%3D 10.2165/00003088- 200443110-00002 15301575 (Pubitemid 39159001)
35. M Pechevis CE Clarke P Vieregge B Khoshnood C Deschaseaux-Voinet G Berdeaux M Ziegler 2005 Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study Eur J Neurol 12 12 956 963 1:STN:280:DC%2BD2MnksVGktw%3D%3D 10.1111/j.1468-1331.2005.01096.x 16324089 (Pubitemid 41820050)
36. WH Poewe G Deuschl A Gordin ER Kultalahti M Leinonen 2002 Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study) Acta Neurol Scand 105 4 245 255 1:CAS:528: DC%2BD38XjvFGgs70%3D 10.1034/j.1600-0404.2002.1o174.x 11939936 (Pubitemid 34407226)
37. JR Pollard 2008 Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy Curr Opin Investig Drugs 9 1 101 107 1:CAS:528: DC%2BD1cXitVOgt7o%3D 18183537
38. A Schrag 2005 Entacapone in the treatment of Parkinson's disease Lancet Neurol 4 6 366 370 S1474-4422(05)70098-3 1:CAS:528:DC%2BD2MXls1eis7c%3D 10.1016/S1474-4422(05)70098-3 15907741 (Pubitemid 40720033)
39. Stocchi F (2009) The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. Parkinsonism Relat Disord 15(Suppl 3):S68-S71. doi: S1353-8020(09)70784-9
40. Stocchi F, Tagliati M, Olanow CW (2008) Treatment of levodopa-induced motor complications. Mov Disord 23(Suppl 3):S599-S612. doi: 10.1002/mds.22052
41. A Storch C Trenkwalder C Oehlwein J Winkelmann U Polzer HP Hundemer J Schwarz 2005 High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias Parkinsonism Relat Disord 11 6 393 398 S1353-8020(05)00082-9 10.1016/j.parkreldis.2005.03.005 15993640 (Pubitemid 41317808)
42. B Tousi T Subramanian 2005 The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease Parkinsonism Relat Disord 11 5 333 334 S1353-8020(04)00196-8 10.1016/j.parkreldis.2004.11.003 15949966 (Pubitemid 40982511)
43. L Verhagen Metman P Del Dotto R Natte P van den Munckhof TN Chase 1998 Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease Neurology 51 1 203 206 1:STN:280:DyaK1czjslGlsg%3D%3D 9674803 (Pubitemid 28345384)
44. L Verhagen Metman P Del Dotto P van den Munckhof J Fang MM Mouradian TN Chase 1998 Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease Neurology 50 5 1323 1326 1:STN:280:DyaK1c3lsFChsg%3D%3D 9595981 (Pubitemid 28240346)
45. JL Vitek M Giroux 2000 Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia Ann Neurol 47 4 Suppl 1 S131 S140 1:CAS:528:DC%2BD3cXivVOntbg%3D 10762140
46. J Volkmann N Allert J Voges V Sturm A Schnitzler HJ Freund 2004 Long-term results of bilateral pallidal stimulation in Parkinson's disease Ann Neurol 55 6 871 875 10.1002/ana.20091 10.1002/ana.20091 15174022 (Pubitemid 38702583)
47. SW Woods JR Saksa CB Baker SJ Cohen C Tek 2008 Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study J Clin Psychiatry 69 4 546 554 ej07m03338 1:CAS:528:DC%2BD1cXmtFShsbg%3D 10.4088/JCP.v69n0405 18312060
48. TA Zesiewicz KL Sullivan JL Maldonado WO Tatum RA Hauser 2005 Open-label pilot study of levetiracetam (keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease Mov Disord 20 9 1205 1209 10.1002/mds.20563 10.1002/mds.20563 15954135 (Pubitemid 41632212)
49. TA Zesiewicz KL Sullivan RA Hauser J Sanchez-Ramos 2006 Open-label pilot study of levetiracetam (keppra) for the treatment of chorea in Huntington's disease Mov Disord 21 11 1998 2001 10.1002/mds.21061 10.1002/mds.21061 16941461 (Pubitemid 44848955)